In anticipation of the 2021 American Society of Hematology (ASH) Annual Meeting and Exposition, Genmab A/S shared through a press release some of the highlights of the over 20 abstracts involving their medicines and drug development platforms, particularly with their work with epcoritamab (DuoBody®-CD3xCD20). They also announced their plan to host a Virtual R&D Update and ASH Data Review meeting via live webcast.
Epcoritamab is an IgG1-bispecific antibody created to bind to CD3 on T-cells and CD20 on B-cells at the same time, leading to the process of T-cell mediated killing of lymphoma B-cells. In collaboration with AbbVie, Genmab uses their DuoBody technology to develop the drug.
Genmab highlighted presentations on the developing data and results related to the safety and preliminary efficacy of incorporation epcoritamab in different therapies for treating patients with large B-cell lymphoma (Abstract 1413), relapsed/refractory follicular lymphoma (Abstract 3535), and relapsed/refractory chronic lymphocytic leukemia (Abstract 2627). These studies examine the subcutaneous delivery of epcoritaman in addition to the standard treatments for each blood cancer.
Genmab is also involved in the phase 3 trial of using epcoritamab in treatment for patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) (Abstract 3569). Researchers are investigating the impact incorporating epcoritamab into treatment has on overall survival and progression-free survival rates, as well as safety and efficacy, when compared to the standard therapy for patients with R/R DLBCL. The study is currently undergoing enrollment in almost 20 countries.
While not connected with the official program of ASH 2021, a live webcast will be held by Genmab during the week of the meeting. This event will give updates on the company’s research and development and review data being presented at ASH 2021 .
Source: Genmab announces multiple abstracts to be presented at the 63rd Annual Meeting and Exposition of the American Society of Hematology (ASH). (2021, November 4). [Press release]. https://ir.genmab.com/news-releases/news-release-details/genmab-announces-multiple-abstracts-be-presented-63rd-annual